



Cancer Prevention and Control CIRB Meeting Agenda

October 24, 2024

I. Potential Unanticipated Problem and/or the Serious or Continuing Noncompliance

URCC-19075, Multi-center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) (Version Date 09/01/23)

II. Initial Review

NRG-CC014, Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (Version Date 09/05/24)

III. Initial Review

S2408, A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula (Version Date 09/02/24)

IV. Amendment

NWU20-04-01, Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals (Version Date 09/30/24)

V. Amendment Prior to Activation

NRG-CC013, A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation (Version Date 09/30/24)

VI. Continuing Review

A222004, A Randomized Phase III Trial Of Olanzapine Versus Megestrol Acetate For Cancer-Associated Anorexia (Version Date 07/21/23)

VII. Continuing Review

EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Version Date 07/12/24)

VIII. Continuing Review

EA2185, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers (Version Date 08/13/24)

IX. Continuing Review

NWU20-01-03, Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): RELIEF-NAFLD (Version Date 01/23/24)

X. Continuing Review

UAZ22-10-01, Phase IIa, Single-arm, Open-label, Clinical Trial of calcipotriene plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients (Version Date 10/04/24)

XI. Continuing Review

URCC-19178, Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy The GEM-S Study (Version Date 02/09/23)
